Trial Profile
A Phase 3, Randomized, Multi-Center, Multi-National, Open-Label, Active Comparator Study to Evaluate the Efficacy and Safety of Genz-112638 in Patients With Gaucher Disease Type 1 Who Have Reached Therapeutic Goals With Enzyme Replacement Therapy (ENCORE)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Apr 2022
Price :
$35
*
At a glance
- Drugs Eliglustat (Primary) ; Imiglucerase
- Indications Gaucher's disease type I
- Focus Therapeutic Use
- Acronyms ENCORE
- Sponsors Genzyme Corporation
- 04 Dec 2018 Results analyzing bone mineral density T- and Z-scores and occurrence of bone pain and bone crises in 4 clinical trials (NCT00358150, NCT00891202, NCT00943111, and NCT01074944) presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
- 04 Dec 2018 Results of long term pooled safety analysis (n=393) of ENGAGE, ENCORE, EDGE and one other phase II trial presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
- 06 Feb 2017 Results (n=46) assessing long-term (4 years) safety and efficacy of eliglustat, published in the Blood.